201 related articles for article (PubMed ID: 28880238)
21. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
Kopp TI; Andersen V; Tjonneland A; Vogel U
Scand J Gastroenterol; 2015; 50(12):1469-81. PubMed ID: 26109419
[TBL] [Abstract][Full Text] [Related]
22. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
23. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Ikai A; Watanabe M; Sowa Y; Kishimoto M; Yanagisawa A; Fujiwara H; Otsuji E; Sakai T
Int J Oncol; 2016 Mar; 48(3):1297-304. PubMed ID: 26783196
[TBL] [Abstract][Full Text] [Related]
25. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
26. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
27. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
[TBL] [Abstract][Full Text] [Related]
28. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
29. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
30. ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.
Tuy HD; Shiomi H; Mukaisho KI; Naka S; Shimizu T; Sonoda H; Mekata E; Endo Y; Kurumi Y; Sugihara H; Tani M; Tani T
Oncol Lett; 2016 Oct; 12(4):2752-2760. PubMed ID: 27698852
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
[TBL] [Abstract][Full Text] [Related]
32. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
35. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
[TBL] [Abstract][Full Text] [Related]
36. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
37. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
39. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Shah MA; Kemeny N; Hummer A; Drobnjak M; Motwani M; Cordon-Cardo C; Gonen M; Schwartz GK
Clin Cancer Res; 2005 May; 11(9):3296-302. PubMed ID: 15867226
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.
Hénin E; Honorat M; Guitton J; Di Pietro A; Payen L; Tod M
Biopharm Drug Dispos; 2017 Jul; 38(5):351-362. PubMed ID: 28207160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]